Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2009

View Archived Issues

Pimavanserin does not worsen parkinsonism in patients with PD and psychosis

NST-0021 prevents neurodegeneration in vivo in Alzheimer's model

Hydrogen sulphide-releasing latanoprost derivative shows potential for the treatment of glaucoma

Preliminary data show effects on sleep and memory with ramelteon in Parkinson's disease patients

BioSante updates status of LibiGel for FSD in menopausal women

Cytos reports disappointing results from phase IIa trial of hypertension vaccine CYT006-AngQb

Opexa reports preclinical data for autologous stem cell therapy for diabetes

Spectrum acquires former partner RIT Oncology and rights to Zevalin for NHL

Questcor submits sNDA to FDA for H.P. Acthar gel for infantile spasms

Alba Therapeutics to initiate next clinical trial for larazotide acetate

Cephalon reports positive results from phase II Nuvigil study

Novel dual MEK/ERK inhibitor shows antitumor activity

NicOx initiates proof-of-principle clinical study for NCX-6560

Sopherion completes enrollment in phase III Myocet breast cancer study

Quest forms alliance with IntelligentNano for nanotechnology-based SL-052

Nanobac and Eureka Genomics agree to terms for merger

Merck Serono and Fast Forward to accelerate development of MS treatments

Merck & Co. donates antimalarial candidate to Medicines for Malaria Venture

FDA approves Hologic's DNA tests for high-risk human papillomavirus

FDA accepts IND for Arno Therapeutics' Pan-DAC/Akt inhibitor, AR-42

Y's Therapeutics claims TNF-alpha release inhibitors for modulation of immune responses

Actelion Pharmaceuticals presents novel orexin receptor antagonists

Novel cathepsin C inhibitors described by GlaxoSmithKline

Novel carbostyryl derivatives described by Kyorin Pharmaceutical

Summit Corporation patents novel compounds with potential for Duchenne muscular dystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...